External innovation holds the key for long-term growth
03/12/20 -"Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of Cabometyx, Onivyde, Palovarotene, Decapeptyl and Dysport ..."
Pages
52
Language
English
Published on
03/12/20
You may also be interested by these reports :
29/10/25
The Q3 results exceeded expectations, driven by strong growth in the HIV, respiratory, immunology, oncology, and vaccines portfolio. Consequently, ...
28/10/25
The Q3 operating profitability was slightly behind the street’s expectations, though sales were in line with consensus. The quarterly performance was ...
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...